Long-Term Decline In Cereal Market Poses Structural Challenges For Kellogg, Analyst Says
J.P. Morgan analyst Ken Goldman on Tuesday assigned a Neutral rating on the shares of WK Kellogg Co (NYSE:KLG) with a price forecast of $19.00.
The company reported first-quarter earnings per share of 20 cents, missing the street view of 34 cents. Quarterly sales of $663 million missed the analyst consensus estimate of $679.49 million.
KLG revised its 2025 outlook, now expecting organic net sales to decline 2.0% to 3.0%, and adjusted EBITDA to be flat or down 2.0%, versus previous forecasts of milder declines and EBITDA growth.The outlook reflects modest tariff impacts on raw materials, assuming continued trade exemptions with Canada and Mexico, though the company warned future tariff changes could further affect results.
On the positive side, the analyst sees significant potential for margin expansion and believes the stock's current low valuation could help support its price.
However, the analyst remains cautious about the company's projections for EBITDA margin gains, especially given weak sales trends.
The long-term decline in the cereal market poses structural challenges, and upcoming restructuring and capital expenditures will strain cash flow, noted the analyst.
The analyst said KLG shares should trade at a discount compared to larger packaged food companies due to ongoing difficulties in the cereal category, substantial upcoming spending on capital projects and restructuring, and the company's smaller scale.
Price Action: KLG shares closed lower by 3.90% to $17.23 on Wednesday.
Read Next:Photo by JHVEPhoto via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Long-Term Decline In Cereal Market Poses Structural Challenges For Kellogg, Analyst Says originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Costco Posts 6.8% Sales Growth in May, Slightly Slower Than April
Costco reported a 6.8% increase in sales for the month of May compared to May 2024. Comparable store sales rose less than analysts had expected, according to a note from JPMorgan analysts. The analysts said cooler than average weather in May could have slowed sales, while purchases rushed by tariffs likely peaked in March and Wholesale (COST) after the bell Wednesday said that its sales in May grew 6.8% year-over-year to $20.97 billion, slightly slower growth than the 7% that it saw in April compared to April 2024. The warehouse retailer's comparable store sales rose 4.1% in the U.S., 4.3% for the total company, and online sales grew 11.6% in May. The 5.5% comparable sales increase in the U.S., when excluding the impact of gas prices and foreign exchange rates, came in below the 6.4% analyst consensus, JPMorgan analysts wrote following the sales report. The analysts wrote that Costco's sales results are in line with some other retailers that mentioned in recent earnings reports that May sales were weaker than April or March, largely due to weather—including a cooler-than-normal Memorial Day weekend in parts of the country. Costco said it doesn't typically cite weather as a factor unless there is an extreme weather event, per the analysts. Any big purchases that consumers made ahead of schedule because of fears that tariffs would raise prices likely peaked in March and April, as executives said in last week's earnings call that they were seeing few tariff-motivated purchases at this point, according to the JPM analysts. The analysts said Costco's comparable sales growth could be pressured in the next few months as Costco laps the popular sales of its gold bars, which frequently sold out quickly when they were available. The retailer narrowly beat estimates in its fiscal third-quarter report, as other analysts have said Costco is well-positioned to navigate the tariff environment. Costco shares were little changed shortly ahead of markets opening, and are up nearly 15% since the start of the year but still just below record levels set in February. Read the original article on Investopedia
Yahoo
an hour ago
- Yahoo
Elon Musk's Tesla faces $3bn hit from Trump's ‘big, beautiful bill'
Tesla is facing a $3bn (£2.2bn) hit from Donald Trump's tax and spending bill, highlighting a potential reason why Elon Musk has vowed to 'kill' the legislation. Buried in the US president's 1,000-page bill are plans to eliminate a $7,500 tax incentive for electric vehicle (EV) buyers and ban a similar scheme in California. Wall Street analysts said axing the tax break for drivers would cost Tesla about $1.2bn, while the Californian ban threatens a further $2bn profit hit. The president's 'big, beautiful bill' has prompted a furious reaction from Mr Musk, who left his role as a White House cost-cutting tsar last week. The world's richest man has since called the tax and spending legislation a 'disgusting abomination' and called on US politicians to 'kill the bill'. Ryan Brinkman, a JP Morgan analyst, wrote in a research note that 'Tesla appears to have the most to lose from the shifting regulatory backdrop, perhaps to the tune of $3.2bn'. He expects the measures to cut Tesla's profits in half this year. Mr Musk has been personally lobbying US senators to block the passage of the bill, which is expected to add $2.4 trillion to the US deficit. According to NBC, he called Mike Johnson, the Republican US House speaker, in an effort to save the green tax credit, while he has also amplified the views of US senators who oppose the legislation on X. The billionaire has so far presented his opposition to the bill as a matter of principle, arguing that it undermines the work he did at the department for government efficiency (Doge) to slash government spending in an effort to lower taxes and borrowing. In a post on X, Mr Musk said the bill 'defeats all the cost savings achieved by the Doge team at great personal cost and risk'. In another, he labelled the planned law the 'Debt Slavery Bill'. However, the JP Morgan research highlights the potential personal cost to Mr Musk from the legislation. Much of his wealth is derived from Tesla, which has already suffered as a result of his association with Mr Trump. Sales have slumped in Europe amid a political boycott of the electric vehicles. Mr Musk's net worth has fallen by $64bn so far this year, according to Bloomberg, though he still commands an estimated $368bn fortune. The entrepreneur has sought to rally Republican voters to lobby against the bill and threatened to 'fire all politicians who betrayed the American people' in November's mid-term elections. Mr Musk was the largest political donor in the US last year, giving $290m to encourage voters to elect Mr Trump and other Republicans. Mr Musk had previously defended Mr Trump's vision of cutting electric vehicle subsidies, insisting the changes would 'only help Tesla' by hurting its rivals. 'I think we should get rid of all credits,' he said last year. However, since quitting the White House, Tesla and Mr Musk have taken aim at many of the proposals in Mr Trump's planned bill. Last week, Tesla Energy, its solar and battery storage business, said: 'Ending energy tax credits would threaten America's energy independence and the reliability of our grid.' The rift has angered Mr Trump, Axios reported. The website said Mr Johnson told colleagues Mr Trump was 'pissed off' with the Tesla boss and told reporters he was 'not delighted that Elon did a 180'. The changes to EV credits are expected to hit sales of battery-powered cars across the US. Dan Ives, a technology analyst with Wedbush Securities, said the changes would 'hurt EV demand by 10pc across the industry'. A survey from Insurify, meanwhile, found 45pc of EV buyers said they would not have bought a new car without the $7,500 incentive. It found 36pc of Tesla buyers would have not made a purchase without the benefit. Mr Trump's tax and spending bill passed the House of Representatives by a narrow margin and is now before the Senate. Tesla was contacted for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
